nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—Teniposide—lymphatic system cancer	0.13	0.35	CbGbCtD
Bexarotene—CYP3A4—Cytarabine—lymphatic system cancer	0.0766	0.207	CbGbCtD
Bexarotene—CYP3A4—Teniposide—lymphatic system cancer	0.0755	0.203	CbGbCtD
Bexarotene—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0528	0.142	CbGbCtD
Bexarotene—CYP3A4—Vincristine—lymphatic system cancer	0.0363	0.0979	CbGbCtD
Bexarotene—Arrhythmia—Carmustine—lymphatic system cancer	0.000935	0.00149	CcSEcCtD
Bexarotene—Leukopenia—Bleomycin—lymphatic system cancer	0.000934	0.00149	CcSEcCtD
Bexarotene—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000932	0.00148	CcSEcCtD
Bexarotene—Cardiac disorder—Vincristine—lymphatic system cancer	0.000927	0.00147	CcSEcCtD
Bexarotene—Alopecia—Carmustine—lymphatic system cancer	0.000925	0.00147	CcSEcCtD
Bexarotene—Body temperature increased—Fludarabine—lymphatic system cancer	0.000918	0.00146	CcSEcCtD
Bexarotene—Malnutrition—Carmustine—lymphatic system cancer	0.000911	0.00145	CcSEcCtD
Bexarotene—Erythema—Carmustine—lymphatic system cancer	0.000911	0.00145	CcSEcCtD
Bexarotene—Cough—Bleomycin—lymphatic system cancer	0.000911	0.00145	CcSEcCtD
Bexarotene—Angiopathy—Vincristine—lymphatic system cancer	0.000906	0.00144	CcSEcCtD
Bexarotene—Diarrhoea—Teniposide—lymphatic system cancer	0.000904	0.00144	CcSEcCtD
Bexarotene—Chest pain—Bleomycin—lymphatic system cancer	0.000889	0.00141	CcSEcCtD
Bexarotene—Myalgia—Bleomycin—lymphatic system cancer	0.000889	0.00141	CcSEcCtD
Bexarotene—Alopecia—Vincristine—lymphatic system cancer	0.000883	0.0014	CcSEcCtD
Bexarotene—Back pain—Carmustine—lymphatic system cancer	0.000881	0.0014	CcSEcCtD
Bexarotene—Discomfort—Bleomycin—lymphatic system cancer	0.000878	0.0014	CcSEcCtD
Bexarotene—Chills—Mitoxantrone—lymphatic system cancer	0.000873	0.00139	CcSEcCtD
Bexarotene—Ecchymosis—Methotrexate—lymphatic system cancer	0.000873	0.00139	CcSEcCtD
Bexarotene—Urine output increased—Methotrexate—lymphatic system cancer	0.000873	0.00139	CcSEcCtD
Bexarotene—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000873	0.00139	CcSEcCtD
Bexarotene—Neoplasm—Methotrexate—lymphatic system cancer	0.000873	0.00139	CcSEcCtD
Bexarotene—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000869	0.00138	CcSEcCtD
Bexarotene—Alopecia—Mitoxantrone—lymphatic system cancer	0.00086	0.00137	CcSEcCtD
Bexarotene—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000859	0.00137	CcSEcCtD
Bexarotene—Confusional state—Bleomycin—lymphatic system cancer	0.000859	0.00137	CcSEcCtD
Bexarotene—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000856	0.00136	CcSEcCtD
Bexarotene—Oedema—Bleomycin—lymphatic system cancer	0.000852	0.00135	CcSEcCtD
Bexarotene—Erythema—Mitoxantrone—lymphatic system cancer	0.000847	0.00135	CcSEcCtD
Bexarotene—Infection—Bleomycin—lymphatic system cancer	0.000846	0.00135	CcSEcCtD
Bexarotene—Anaemia—Carmustine—lymphatic system cancer	0.000842	0.00134	CcSEcCtD
Bexarotene—Back pain—Vincristine—lymphatic system cancer	0.000841	0.00134	CcSEcCtD
Bexarotene—Vomiting—Teniposide—lymphatic system cancer	0.00084	0.00134	CcSEcCtD
Bexarotene—Sepsis—Methotrexate—lymphatic system cancer	0.000838	0.00133	CcSEcCtD
Bexarotene—Agitation—Carmustine—lymphatic system cancer	0.000837	0.00133	CcSEcCtD
Bexarotene—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000834	0.00133	CcSEcCtD
Bexarotene—Asthenia—Fludarabine—lymphatic system cancer	0.000834	0.00133	CcSEcCtD
Bexarotene—Rash—Teniposide—lymphatic system cancer	0.000833	0.00133	CcSEcCtD
Bexarotene—Dermatitis—Teniposide—lymphatic system cancer	0.000833	0.00132	CcSEcCtD
Bexarotene—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000829	0.00132	CcSEcCtD
Bexarotene—Headache—Teniposide—lymphatic system cancer	0.000828	0.00132	CcSEcCtD
Bexarotene—Pruritus—Fludarabine—lymphatic system cancer	0.000822	0.00131	CcSEcCtD
Bexarotene—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000821	0.00131	CcSEcCtD
Bexarotene—Back pain—Mitoxantrone—lymphatic system cancer	0.000819	0.0013	CcSEcCtD
Bexarotene—Leukopenia—Carmustine—lymphatic system cancer	0.000815	0.0013	CcSEcCtD
Bexarotene—Anorexia—Bleomycin—lymphatic system cancer	0.000812	0.00129	CcSEcCtD
Bexarotene—Anaemia—Vincristine—lymphatic system cancer	0.000804	0.00128	CcSEcCtD
Bexarotene—Agitation—Vincristine—lymphatic system cancer	0.000799	0.00127	CcSEcCtD
Bexarotene—Polyuria—Methotrexate—lymphatic system cancer	0.000798	0.00127	CcSEcCtD
Bexarotene—Diarrhoea—Fludarabine—lymphatic system cancer	0.000795	0.00126	CcSEcCtD
Bexarotene—Hypertension—Carmustine—lymphatic system cancer	0.000787	0.00125	CcSEcCtD
Bexarotene—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000786	0.00125	CcSEcCtD
Bexarotene—Nausea—Teniposide—lymphatic system cancer	0.000785	0.00125	CcSEcCtD
Bexarotene—Anaemia—Mitoxantrone—lymphatic system cancer	0.000783	0.00124	CcSEcCtD
Bexarotene—Vertigo—Vincristine—lymphatic system cancer	0.000781	0.00124	CcSEcCtD
Bexarotene—Hepatic failure—Methotrexate—lymphatic system cancer	0.00078	0.00124	CcSEcCtD
Bexarotene—Leukopenia—Vincristine—lymphatic system cancer	0.000778	0.00124	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000776	0.00123	CcSEcCtD
Bexarotene—Myalgia—Carmustine—lymphatic system cancer	0.000776	0.00123	CcSEcCtD
Bexarotene—Chest pain—Carmustine—lymphatic system cancer	0.000776	0.00123	CcSEcCtD
Bexarotene—Anxiety—Carmustine—lymphatic system cancer	0.000773	0.00123	CcSEcCtD
Bexarotene—Paraesthesia—Bleomycin—lymphatic system cancer	0.000765	0.00122	CcSEcCtD
Bexarotene—Malaise—Mitoxantrone—lymphatic system cancer	0.000764	0.00121	CcSEcCtD
Bexarotene—Dyspnoea—Bleomycin—lymphatic system cancer	0.000759	0.00121	CcSEcCtD
Bexarotene—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000758	0.00121	CcSEcCtD
Bexarotene—Hypertension—Vincristine—lymphatic system cancer	0.000751	0.00119	CcSEcCtD
Bexarotene—Confusional state—Carmustine—lymphatic system cancer	0.00075	0.00119	CcSEcCtD
Bexarotene—Oedema—Carmustine—lymphatic system cancer	0.000744	0.00118	CcSEcCtD
Bexarotene—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000743	0.00118	CcSEcCtD
Bexarotene—Decreased appetite—Bleomycin—lymphatic system cancer	0.00074	0.00118	CcSEcCtD
Bexarotene—Myalgia—Vincristine—lymphatic system cancer	0.00074	0.00118	CcSEcCtD
Bexarotene—Cough—Mitoxantrone—lymphatic system cancer	0.000739	0.00118	CcSEcCtD
Bexarotene—Infection—Carmustine—lymphatic system cancer	0.000739	0.00117	CcSEcCtD
Bexarotene—Vomiting—Fludarabine—lymphatic system cancer	0.000739	0.00117	CcSEcCtD
Bexarotene—Rash—Fludarabine—lymphatic system cancer	0.000732	0.00116	CcSEcCtD
Bexarotene—Dermatitis—Fludarabine—lymphatic system cancer	0.000732	0.00116	CcSEcCtD
Bexarotene—Hypertension—Mitoxantrone—lymphatic system cancer	0.000731	0.00116	CcSEcCtD
Bexarotene—Pain—Bleomycin—lymphatic system cancer	0.000728	0.00116	CcSEcCtD
Bexarotene—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000728	0.00116	CcSEcCtD
Bexarotene—Headache—Fludarabine—lymphatic system cancer	0.000728	0.00116	CcSEcCtD
Bexarotene—Tachycardia—Carmustine—lymphatic system cancer	0.000726	0.00115	CcSEcCtD
Bexarotene—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000721	0.00115	CcSEcCtD
Bexarotene—Chest pain—Mitoxantrone—lymphatic system cancer	0.000721	0.00115	CcSEcCtD
Bexarotene—Myalgia—Mitoxantrone—lymphatic system cancer	0.000721	0.00115	CcSEcCtD
Bexarotene—Anxiety—Mitoxantrone—lymphatic system cancer	0.000719	0.00114	CcSEcCtD
Bexarotene—Lethargy—Methotrexate—lymphatic system cancer	0.000715	0.00114	CcSEcCtD
Bexarotene—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000715	0.00114	CcSEcCtD
Bexarotene—Discomfort—Mitoxantrone—lymphatic system cancer	0.000712	0.00113	CcSEcCtD
Bexarotene—Oedema—Vincristine—lymphatic system cancer	0.00071	0.00113	CcSEcCtD
Bexarotene—Anorexia—Carmustine—lymphatic system cancer	0.000709	0.00113	CcSEcCtD
Bexarotene—Infection—Vincristine—lymphatic system cancer	0.000705	0.00112	CcSEcCtD
Bexarotene—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000702	0.00112	CcSEcCtD
Bexarotene—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000701	0.00111	CcSEcCtD
Bexarotene—Confusional state—Mitoxantrone—lymphatic system cancer	0.000697	0.00111	CcSEcCtD
Bexarotene—Nervous system disorder—Vincristine—lymphatic system cancer	0.000696	0.00111	CcSEcCtD
Bexarotene—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000695	0.0011	CcSEcCtD
Bexarotene—Oedema—Mitoxantrone—lymphatic system cancer	0.000691	0.0011	CcSEcCtD
Bexarotene—Nausea—Fludarabine—lymphatic system cancer	0.00069	0.0011	CcSEcCtD
Bexarotene—Infection—Mitoxantrone—lymphatic system cancer	0.000687	0.00109	CcSEcCtD
Bexarotene—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000686	0.00109	CcSEcCtD
Bexarotene—Shock—Mitoxantrone—lymphatic system cancer	0.00068	0.00108	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000677	0.00108	CcSEcCtD
Bexarotene—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000677	0.00108	CcSEcCtD
Bexarotene—Anorexia—Vincristine—lymphatic system cancer	0.000677	0.00108	CcSEcCtD
Bexarotene—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000675	0.00107	CcSEcCtD
Bexarotene—Body temperature increased—Bleomycin—lymphatic system cancer	0.000673	0.00107	CcSEcCtD
Bexarotene—Insomnia—Carmustine—lymphatic system cancer	0.000672	0.00107	CcSEcCtD
Bexarotene—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000671	0.00107	CcSEcCtD
Bexarotene—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000668	0.00106	CcSEcCtD
Bexarotene—Paraesthesia—Carmustine—lymphatic system cancer	0.000668	0.00106	CcSEcCtD
Bexarotene—Mood swings—Methotrexate—lymphatic system cancer	0.000664	0.00106	CcSEcCtD
Bexarotene—Dyspnoea—Carmustine—lymphatic system cancer	0.000663	0.00105	CcSEcCtD
Bexarotene—Somnolence—Carmustine—lymphatic system cancer	0.000661	0.00105	CcSEcCtD
Bexarotene—Anorexia—Mitoxantrone—lymphatic system cancer	0.000659	0.00105	CcSEcCtD
Bexarotene—Ataxia—Methotrexate—lymphatic system cancer	0.000659	0.00105	CcSEcCtD
Bexarotene—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000647	0.00103	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000647	0.00103	CcSEcCtD
Bexarotene—Decreased appetite—Carmustine—lymphatic system cancer	0.000646	0.00103	CcSEcCtD
Bexarotene—Insomnia—Vincristine—lymphatic system cancer	0.000642	0.00102	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000642	0.00102	CcSEcCtD
Bexarotene—Paraesthesia—Vincristine—lymphatic system cancer	0.000637	0.00101	CcSEcCtD
Bexarotene—Pain—Carmustine—lymphatic system cancer	0.000636	0.00101	CcSEcCtD
Bexarotene—Constipation—Carmustine—lymphatic system cancer	0.000636	0.00101	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00063	0.001	CcSEcCtD
Bexarotene—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000628	0.000998	CcSEcCtD
Bexarotene—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000621	0.000987	CcSEcCtD
Bexarotene—Decreased appetite—Vincristine—lymphatic system cancer	0.000617	0.000981	CcSEcCtD
Bexarotene—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000616	0.00098	CcSEcCtD
Bexarotene—Somnolence—Mitoxantrone—lymphatic system cancer	0.000614	0.000977	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000613	0.000974	CcSEcCtD
Bexarotene—Feeling abnormal—Carmustine—lymphatic system cancer	0.000613	0.000974	CcSEcCtD
Bexarotene—Fatigue—Vincristine—lymphatic system cancer	0.000612	0.000973	CcSEcCtD
Bexarotene—Asthenia—Bleomycin—lymphatic system cancer	0.000611	0.000972	CcSEcCtD
Bexarotene—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000608	0.000967	CcSEcCtD
Bexarotene—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000608	0.000967	CcSEcCtD
Bexarotene—Pain—Vincristine—lymphatic system cancer	0.000607	0.000965	CcSEcCtD
Bexarotene—Constipation—Vincristine—lymphatic system cancer	0.000607	0.000965	CcSEcCtD
Bexarotene—Pruritus—Bleomycin—lymphatic system cancer	0.000603	0.000958	CcSEcCtD
Bexarotene—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000601	0.000955	CcSEcCtD
Bexarotene—Eosinophilia—Methotrexate—lymphatic system cancer	0.0006	0.000953	CcSEcCtD
Bexarotene—Fatigue—Mitoxantrone—lymphatic system cancer	0.000596	0.000948	CcSEcCtD
Bexarotene—Pancreatitis—Methotrexate—lymphatic system cancer	0.000594	0.000944	CcSEcCtD
Bexarotene—Pain—Mitoxantrone—lymphatic system cancer	0.000591	0.00094	CcSEcCtD
Bexarotene—Constipation—Mitoxantrone—lymphatic system cancer	0.000591	0.00094	CcSEcCtD
Bexarotene—Abdominal pain—Carmustine—lymphatic system cancer	0.000588	0.000935	CcSEcCtD
Bexarotene—Body temperature increased—Carmustine—lymphatic system cancer	0.000588	0.000935	CcSEcCtD
Bexarotene—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00058	0.000923	CcSEcCtD
Bexarotene—Pancytopenia—Methotrexate—lymphatic system cancer	0.000575	0.000914	CcSEcCtD
Bexarotene—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00057	0.000906	CcSEcCtD
Bexarotene—Dysuria—Methotrexate—lymphatic system cancer	0.000566	0.0009	CcSEcCtD
Bexarotene—Neutropenia—Methotrexate—lymphatic system cancer	0.000566	0.0009	CcSEcCtD
Bexarotene—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000565	0.000899	CcSEcCtD
Bexarotene—Body temperature increased—Vincristine—lymphatic system cancer	0.000561	0.000892	CcSEcCtD
Bexarotene—Abdominal pain—Vincristine—lymphatic system cancer	0.000561	0.000892	CcSEcCtD
Bexarotene—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000558	0.000887	CcSEcCtD
Bexarotene—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000553	0.000879	CcSEcCtD
Bexarotene—Hypersensitivity—Carmustine—lymphatic system cancer	0.000548	0.000871	CcSEcCtD
Bexarotene—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000546	0.000869	CcSEcCtD
Bexarotene—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000546	0.000869	CcSEcCtD
Bexarotene—Pneumonia—Methotrexate—lymphatic system cancer	0.000543	0.000864	CcSEcCtD
Bexarotene—Vomiting—Bleomycin—lymphatic system cancer	0.000542	0.000861	CcSEcCtD
Bexarotene—Rash—Bleomycin—lymphatic system cancer	0.000537	0.000854	CcSEcCtD
Bexarotene—Dermatitis—Bleomycin—lymphatic system cancer	0.000537	0.000853	CcSEcCtD
Bexarotene—Asthenia—Carmustine—lymphatic system cancer	0.000533	0.000848	CcSEcCtD
Bexarotene—Stomatitis—Methotrexate—lymphatic system cancer	0.000526	0.000837	CcSEcCtD
Bexarotene—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000525	0.000835	CcSEcCtD
Bexarotene—Hypersensitivity—Vincristine—lymphatic system cancer	0.000523	0.000831	CcSEcCtD
Bexarotene—Sweating—Methotrexate—lymphatic system cancer	0.000518	0.000823	CcSEcCtD
Bexarotene—Haematuria—Methotrexate—lymphatic system cancer	0.000515	0.000819	CcSEcCtD
Bexarotene—Epistaxis—Methotrexate—lymphatic system cancer	0.000509	0.00081	CcSEcCtD
Bexarotene—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000509	0.00081	CcSEcCtD
Bexarotene—Asthenia—Vincristine—lymphatic system cancer	0.000509	0.00081	CcSEcCtD
Bexarotene—Diarrhoea—Carmustine—lymphatic system cancer	0.000509	0.000809	CcSEcCtD
Bexarotene—Nausea—Bleomycin—lymphatic system cancer	0.000506	0.000804	CcSEcCtD
Bexarotene—Asthenia—Mitoxantrone—lymphatic system cancer	0.000496	0.000789	CcSEcCtD
Bexarotene—Dizziness—Carmustine—lymphatic system cancer	0.000492	0.000782	CcSEcCtD
Bexarotene—Haemoglobin—Methotrexate—lymphatic system cancer	0.000487	0.000775	CcSEcCtD
Bexarotene—Diarrhoea—Vincristine—lymphatic system cancer	0.000486	0.000772	CcSEcCtD
Bexarotene—Haemorrhage—Methotrexate—lymphatic system cancer	0.000485	0.000771	CcSEcCtD
Bexarotene—Pharyngitis—Methotrexate—lymphatic system cancer	0.000481	0.000765	CcSEcCtD
Bexarotene—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000479	0.000761	CcSEcCtD
Bexarotene—Urethral disorder—Methotrexate—lymphatic system cancer	0.000475	0.000756	CcSEcCtD
Bexarotene—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000473	0.000752	CcSEcCtD
Bexarotene—Vomiting—Carmustine—lymphatic system cancer	0.000473	0.000752	CcSEcCtD
Bexarotene—Dizziness—Vincristine—lymphatic system cancer	0.000469	0.000746	CcSEcCtD
Bexarotene—Rash—Carmustine—lymphatic system cancer	0.000469	0.000745	CcSEcCtD
Bexarotene—Dermatitis—Carmustine—lymphatic system cancer	0.000468	0.000745	CcSEcCtD
Bexarotene—Headache—Carmustine—lymphatic system cancer	0.000466	0.000741	CcSEcCtD
Bexarotene—Eye disorder—Methotrexate—lymphatic system cancer	0.000453	0.00072	CcSEcCtD
Bexarotene—Tinnitus—Methotrexate—lymphatic system cancer	0.000452	0.000719	CcSEcCtD
Bexarotene—Vomiting—Vincristine—lymphatic system cancer	0.000451	0.000718	CcSEcCtD
Bexarotene—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00045	0.000715	CcSEcCtD
Bexarotene—Rash—Vincristine—lymphatic system cancer	0.000448	0.000712	CcSEcCtD
Bexarotene—Dermatitis—Vincristine—lymphatic system cancer	0.000447	0.000711	CcSEcCtD
Bexarotene—Headache—Vincristine—lymphatic system cancer	0.000445	0.000707	CcSEcCtD
Bexarotene—Nausea—Carmustine—lymphatic system cancer	0.000442	0.000702	CcSEcCtD
Bexarotene—Angiopathy—Methotrexate—lymphatic system cancer	0.00044	0.000699	CcSEcCtD
Bexarotene—Vomiting—Mitoxantrone—lymphatic system cancer	0.000439	0.000699	CcSEcCtD
Bexarotene—Rash—Mitoxantrone—lymphatic system cancer	0.000436	0.000693	CcSEcCtD
Bexarotene—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000435	0.000692	CcSEcCtD
Bexarotene—Chills—Methotrexate—lymphatic system cancer	0.000435	0.000692	CcSEcCtD
Bexarotene—Headache—Mitoxantrone—lymphatic system cancer	0.000433	0.000689	CcSEcCtD
Bexarotene—Alopecia—Methotrexate—lymphatic system cancer	0.000428	0.000681	CcSEcCtD
Bexarotene—Erythema—Methotrexate—lymphatic system cancer	0.000422	0.000671	CcSEcCtD
Bexarotene—Malnutrition—Methotrexate—lymphatic system cancer	0.000422	0.000671	CcSEcCtD
Bexarotene—Nausea—Vincristine—lymphatic system cancer	0.000422	0.00067	CcSEcCtD
Bexarotene—Dysgeusia—Methotrexate—lymphatic system cancer	0.000413	0.000657	CcSEcCtD
Bexarotene—Nausea—Mitoxantrone—lymphatic system cancer	0.000411	0.000653	CcSEcCtD
Bexarotene—Back pain—Methotrexate—lymphatic system cancer	0.000408	0.000649	CcSEcCtD
Bexarotene—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000392	0.000623	CcSEcCtD
Bexarotene—Anaemia—Methotrexate—lymphatic system cancer	0.00039	0.00062	CcSEcCtD
Bexarotene—Malaise—Methotrexate—lymphatic system cancer	0.000381	0.000605	CcSEcCtD
Bexarotene—Vertigo—Methotrexate—lymphatic system cancer	0.000379	0.000603	CcSEcCtD
Bexarotene—Leukopenia—Methotrexate—lymphatic system cancer	0.000378	0.000601	CcSEcCtD
Bexarotene—Cough—Methotrexate—lymphatic system cancer	0.000368	0.000585	CcSEcCtD
Bexarotene—Arthralgia—Methotrexate—lymphatic system cancer	0.000359	0.000571	CcSEcCtD
Bexarotene—Chest pain—Methotrexate—lymphatic system cancer	0.000359	0.000571	CcSEcCtD
Bexarotene—Myalgia—Methotrexate—lymphatic system cancer	0.000359	0.000571	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000357	0.000567	CcSEcCtD
Bexarotene—Discomfort—Methotrexate—lymphatic system cancer	0.000355	0.000564	CcSEcCtD
Bexarotene—Confusional state—Methotrexate—lymphatic system cancer	0.000347	0.000552	CcSEcCtD
Bexarotene—Infection—Methotrexate—lymphatic system cancer	0.000342	0.000544	CcSEcCtD
Bexarotene—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000338	0.000537	CcSEcCtD
Bexarotene—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000337	0.000536	CcSEcCtD
Bexarotene—Skin disorder—Methotrexate—lymphatic system cancer	0.000335	0.000532	CcSEcCtD
Bexarotene—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000333	0.000529	CcSEcCtD
Bexarotene—Anorexia—Methotrexate—lymphatic system cancer	0.000328	0.000522	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000314	0.000499	CcSEcCtD
Bexarotene—Insomnia—Methotrexate—lymphatic system cancer	0.000311	0.000495	CcSEcCtD
Bexarotene—Paraesthesia—Methotrexate—lymphatic system cancer	0.000309	0.000492	CcSEcCtD
Bexarotene—Dyspnoea—Methotrexate—lymphatic system cancer	0.000307	0.000488	CcSEcCtD
Bexarotene—Somnolence—Methotrexate—lymphatic system cancer	0.000306	0.000487	CcSEcCtD
Bexarotene—Dyspepsia—Methotrexate—lymphatic system cancer	0.000303	0.000482	CcSEcCtD
Bexarotene—Decreased appetite—Methotrexate—lymphatic system cancer	0.000299	0.000476	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000297	0.000473	CcSEcCtD
Bexarotene—Fatigue—Methotrexate—lymphatic system cancer	0.000297	0.000472	CcSEcCtD
Bexarotene—Pain—Methotrexate—lymphatic system cancer	0.000295	0.000468	CcSEcCtD
Bexarotene—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000284	0.000451	CcSEcCtD
Bexarotene—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000282	0.000448	CcSEcCtD
Bexarotene—Abdominal pain—Methotrexate—lymphatic system cancer	0.000272	0.000433	CcSEcCtD
Bexarotene—Body temperature increased—Methotrexate—lymphatic system cancer	0.000272	0.000433	CcSEcCtD
Bexarotene—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000254	0.000403	CcSEcCtD
Bexarotene—Asthenia—Methotrexate—lymphatic system cancer	0.000247	0.000393	CcSEcCtD
Bexarotene—Pruritus—Methotrexate—lymphatic system cancer	0.000244	0.000387	CcSEcCtD
Bexarotene—Diarrhoea—Methotrexate—lymphatic system cancer	0.000236	0.000375	CcSEcCtD
Bexarotene—Dizziness—Methotrexate—lymphatic system cancer	0.000228	0.000362	CcSEcCtD
Bexarotene—Vomiting—Methotrexate—lymphatic system cancer	0.000219	0.000348	CcSEcCtD
Bexarotene—Rash—Methotrexate—lymphatic system cancer	0.000217	0.000345	CcSEcCtD
Bexarotene—Dermatitis—Methotrexate—lymphatic system cancer	0.000217	0.000345	CcSEcCtD
Bexarotene—Headache—Methotrexate—lymphatic system cancer	0.000216	0.000343	CcSEcCtD
Bexarotene—Nausea—Methotrexate—lymphatic system cancer	0.000205	0.000325	CcSEcCtD
